DiaMedica to Present Results of Monoclonal Antibody for Type 2 Diabetes at the Biennial IDF World Diabetes Congress Conference
September 19 2011 - 4:02PM
Marketwired
DiaMedica (TSX VENTURE: DMA) today announces that it has been
invited to present its late-breaking abstract for a poster and
presentation covering results of pre-clinical studies of DM-204 for
the treatment of Type 2 diabetes. The material will be presented on
December 5, 2011 at the 21st biennial World Diabetes Congress
organized by the International Diabetes Federation (IDF) in Dubai,
United Arab Emirates.
The poster and presentation is titled "Novel DM-204 monoclonal
antibody triggers insulin secretion, insulin sensitivity and
reduction in blood pressure." The Company previously released
high-level results that animals acutely treated with DM-204
demonstrated a 291% increase in maximal glucose infusion rate (p
greater than 0.0035) measured in the hyperinsulinemic euglycemic
clamp model. In a separate study, DM-204 lowered systolic blood
pressure by 15 mmHg (p less than 0.05).
"We look forward to sharing the exceptional results of our
DM-204 Type 2 diabetes program at the IDF World Diabetes Congress
that is expected to draw more than 15,000 participants and is one
of the largest and most important healthcare conferences in the
world", stated Dr. Mark Williams, Vice President of Research at
DiaMedica who will be presenting the results of DiaMedica's novel
monoclonal antibody to treat both Type 2 diabetes and one of its
major complications, high blood pressure.
About DiaMedica
DiaMedica is a biopharmaceutical company that has developed
novel therapeutic compounds aimed to improve the lives of patients
with diabetes and other major, medically-unmet diseases.
DiaMedica's lead compound, DM-199, represents a novel approach to
treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting
the autoimmune attack on beta cells; 2) proliferating insulin
producing beta cells and 3) improving glucose control.
DiaMedica is also developing DM-204, a monoclonal antibody that
inhibits the enzyme glycogen synthase kinase 3 beta (GSK3B). In
preclinical studies, DM-204 significantly improved glucose control
and decreased blood pressure.
The company is listed on the TSX Venture Exchange under the
trading symbol 'DMA'.
Caution Regarding Forward-Looking Information
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Company's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Contacts: DiaMedica Inc. Rick Pauls President & CEO
204.477.7590 204.453.3745 (FAX) rpauls@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024